key: cord-0768421-idj2q3r8
authors: Penel, Nicolas; Bonvalot, Sylvie; Minard, Véronique; Orbach, Daniel; Gouin, François; Corradini, Nadège; Brahmi, Mehdi; Marec-Berard, Perrine; Briand, Sylvain; Gaspar, Nathalie; Llacer, Carmen; Carrere, Sébastien; Dufresne, Armelle; Le Cesne, Axel; Blay, Jean-Yves
title: Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
date: 2020-04-01
journal: Bull Cancer
DOI: 10.1016/j.bulcan.2020.03.009
sha: 8e5a17eee48c5bdcf6c93867963fc2a60a9c16cc
doc_id: 768421
cord_uid: idj2q3r8

nan

Regarding the COVID-19 outbreak, we propose an adaptation of current recommendations for clinical practice. Patients with suspected COVID-19 should be screened for the presence of the virus. If confirmed or highly suspected (clinically or CT-scan), any treatment must be postponed at least 15 days after the start of the symptoms and when the patient has recovered. Multidisciplinary tumor boards remain at your disposition for virtual discussion. Contact the manager of your local MDT. lung metastases without extra-thoracic extension and accessible to chest surgery; soft tissue sarcomas: second-lien treatment and beyond may be prescribed according to practice recommendations: oral treatments (pazopanib, or even regorafenib) may be preferred to limit the movement of patients for non-liposarcoma sarcoma. For liposarcomes: trabectedin or eribulin; GIST: the recommendations apply with imatinib and in the metastatic phase (then sunitinib and regorafenib); bone sarcomas with metastasis at diagnosis: classical first-line treatment, e.g. VDC-IE for Ewing sarcoma; metastatic relapse of bone sarcoma: topotecan and cyclophosphamide for Ewing's sarcoma; no standard of care for osteosarcomas (discuss anti-angiogenic treatment, e.g. regorafenib or pazopanib).

Déclaration de liens d'intérêts : les auteurs déclarent ne pas avoir de liens d'intérêts.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

5 Centre Léon-Bérard